From Financial Modeling Prep: 2024-12-31 03:07:00

Stifel analysts raised Glaukos Corporation’s price target to $175, citing confidence in the iDose technology. Surgeons trained in iDose reported strong results, with projections pointing to robust sales in 2024 and significant upside in 2025. Improved reimbursement processes and high Net Promoter Score of 69 contribute to optimism for the company’s future growth and leadership in ophthalmic solutions.



Read more at Financial Modeling Prep:: Glaukos Price Target Boosted to $175 as iDose Surp…